Serum Institute, Pune-based Serum Institute, the country’s largest pharmaceutical company, has started production of the first batch of Kovavax. Serum Institute tweeted on Friday saying that it has achieved a new position. This week, we have started manufacturing the first batch of the Kovid-19 vaccine prepared by Novavaxon, which has been named Kovovax in India.
Significantly, Serum Institute is producing Oxford-AstraZeneca’s Kovid vaccine ‘Covidshield’ in India. Clinical trial of its second vaccine ‘Kovovax’ is also going on in the country. The Drug Controller General of India (DCGI) has approved amendments to the protocol for conducting the third clinical trial of ‘Kovovax’.
— SerumInstituteIndia (@SerumInstIndia) June 25, 2021
Earlier, DCGI had given permission to Serum Institute of India (SII) to make Russia’s Sputnik-V vaccine.
Also read: Clinical trial of the third phase of SII’s second vaccine ‘Kovovax’ may start by mid-June